143 related articles for article (PubMed ID: 26706501)
1. Preparation and in vitro characterisation of bioactive mesoporous silica microparticles for drug delivery applications.
Prokopowicz M; Czarnobaj K; Szewczyk A; Sawicki W
Mater Sci Eng C Mater Biol Appl; 2016 Mar; 60():7-18. PubMed ID: 26706501
[TBL] [Abstract][Full Text] [Related]
2. Bioactive silica-based drug delivery systems containing doxorubicin hydrochloride: in vitro studies.
Prokopowicz M; Zegliński J; Gandhi A; Sawicki W; Tofail SA
Colloids Surf B Biointerfaces; 2012 May; 93():249-59. PubMed ID: 22325320
[TBL] [Abstract][Full Text] [Related]
3. Bioactive silica-based nanomaterials for doxorubicin delivery: evaluation of structural properties associated with release rate.
Prokopowicz M
Mater Sci Eng C Mater Biol Appl; 2013 Oct; 33(7):3942-50. PubMed ID: 23910300
[TBL] [Abstract][Full Text] [Related]
4. Formulation and In Vitro Characterization of Bioactive Mesoporous Silica with Doxorubicin and Metronidazole Intended for Bone Treatment and Regeneration.
Czarnobaj K; Prokopowicz M; Sawicki W
AAPS PharmSciTech; 2017 Nov; 18(8):3163-3171. PubMed ID: 28534298
[TBL] [Abstract][Full Text] [Related]
5. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
6. Formulation, characterisation and in vitro studies of doxorubicin-loaded silica-polydimethylsiloxane granules.
Prokopowicz M
Eur J Pharm Sci; 2015 Jan; 66():10-9. PubMed ID: 25281914
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation.
Chen B; Wang Z; Quan G; Peng X; Pan X; Wang R; Xu Y; Li G; Wu C
Int J Nanomedicine; 2012; 7():199-209. PubMed ID: 22275835
[TBL] [Abstract][Full Text] [Related]
8. Surface-Activated Fibre-Like SBA-15 as Drug Carriers for Bone Diseases.
Prokopowicz M; Żeglinski J; Szewczyk A; Skwira A; Walker G
AAPS PharmSciTech; 2018 Dec; 20(1):17. PubMed ID: 30574669
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of pH-Responsive Biodegradable Mesoporous Silica-Calcium Phosphate Hybrid Nanoparticles as a High Potential Drug Carrier.
He Y; Zeng B; Liang S; Long M; Xu H
ACS Appl Mater Interfaces; 2017 Dec; 9(51):44402-44409. PubMed ID: 29215868
[TBL] [Abstract][Full Text] [Related]
10. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
[TBL] [Abstract][Full Text] [Related]
11. Controllable self-assembly of mesoporous hydroxyapatite.
Chen J; Wang Z; Wen Z; Yang S; Wang J; Zhang Q
Colloids Surf B Biointerfaces; 2015 Mar; 127():47-53. PubMed ID: 25638722
[TBL] [Abstract][Full Text] [Related]
12. The properties of mesoporous silica nanoparticles functionalized with different PEG-chain length via the disulfide bond linker and drug release in glutathione medium.
Xie Z; Gong H; Liu M; Zhu H; Sun H
J Biomater Sci Polym Ed; 2016; 27(1):55-68. PubMed ID: 26540096
[TBL] [Abstract][Full Text] [Related]
13. Co-synthesis and drug delivery properties of mesoporous hydroxyapatite-silica composites.
Zhao YF; Loo SC; Ma J
J Nanosci Nanotechnol; 2009 Jun; 9(6):3720-7. PubMed ID: 19504909
[TBL] [Abstract][Full Text] [Related]
14. Uniform and size-tunable mesoporous silica with fibrous morphology for drug delivery.
Gai S; Yang P; Ma P; Wang L; Li C; Zhang M; Jun L
Dalton Trans; 2012 Apr; 41(15):4511-6. PubMed ID: 22373780
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, amino-functionalization of mesoporous silica and its adsorption of Cr(VI).
Li J; Miao X; Hao Y; Zhao J; Sun X; Wang L
J Colloid Interface Sci; 2008 Feb; 318(2):309-14. PubMed ID: 18036539
[TBL] [Abstract][Full Text] [Related]
16. An in situ synthesis of mesoporous SBA-16/hydroxyapatite for ciprofloxacin release: in vitro stability and cytocompatibility studies.
Andrade GF; Gomide VS; da Silva Júnior AC; Goes AM; de Sousa EM
J Mater Sci Mater Med; 2014 Nov; 25(11):2527-40. PubMed ID: 25056197
[TBL] [Abstract][Full Text] [Related]
17. Ordered mesoporous silica modified with lanthanum for ibuprofen loading and release behaviour.
Goscianska J; Olejnik A; Nowak I; Marciniak M; Pietrzak R
Eur J Pharm Biopharm; 2015 Aug; 94():550-8. PubMed ID: 26170160
[TBL] [Abstract][Full Text] [Related]
18. Luminescence functionalization of mesoporous silica with different morphologies and applications as drug delivery systems.
Yang P; Quan Z; Lu L; Huang S; Lin J
Biomaterials; 2008 Feb; 29(6):692-702. PubMed ID: 17996294
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyapatite/mesoporous silica coated gold nanorods with improved degradability as a multi-responsive drug delivery platform.
Song Z; Liu Y; Shi J; Ma T; Zhang Z; Ma H; Cao S
Mater Sci Eng C Mater Biol Appl; 2018 Feb; 83():90-98. PubMed ID: 29208292
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxyapatite.
Hao X; Hu X; Zhang C; Chen S; Li Z; Yang X; Liu H; Jia G; Liu D; Ge K; Liang XJ; Zhang J
ACS Nano; 2015 Oct; 9(10):9614-25. PubMed ID: 26316321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
